BioNTech hopes to move into cancer drugs

Losses at German pharmaceutical company BioNTech quadrupled in the second quarter compared to the previous year. Now the company is confident in a change of strategy towards new cancer treatments after a sharp drop in sales of its COVID-19 vaccine. BioNTech reported a second-quarter net loss of €807.8 million.

Teile diesen Beitrag:

BELIEBTE BEITRÄGE
FOLGEN SIE UNS
Like uns auf Facebook
Folge uns auf Twitter
Abonniere unseren Kanal
Tick Tack
LIVEÜBERTRAGUNG